Trials / Not Yet Recruiting
Not Yet RecruitingNCT07252752
Dopamine and Insulin in Psychosis
Dopamine and Insulin in Psychosis: Imaging the Effects of Intranasal Insulin on Dopamine Transmission
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- Sponsor
- Medical University of Vienna · Academic / Other
- Sex
- All
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
Patients with schizophrenia have a high risk of developing metabolic disorders and current evidence points to an overlap in mechanisms underlying psychiatric symptoms and metabolic disturbances. The main goal of this study is to investigate effects of brain insulin on dopamine signaling and energy metabolism in patients with schizophrenia experiencing their first psychotic episode (FEP). To this end, patients with schizophrenia and healthy volunteers will undergo two \[11C\]-(+)-PHNO positron emission (PET) scans to measure the changes in dopamine receptor availability after nasally applied insulin, as well as single proton magnetic resonance spectroscopy (1H-MRS) to assess the impact of intranasal insulin on levels of glucose and glutamate in the hippocampus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Intranasal Insulin | 160 IU intranasal insulin is administered using precision air pumps twice: 15 min prior to the PET scan and 35 min prior to the 1H-MRS scan |
| DRUG | Placebo | Insulin-free dilution buffer is administered using precision air pumps 15 min prior to the PET scan |
| DRUG | Low dose insulin infusion | 2.5 mU/kg insulin in 100 ml isotonic saline is infused intravenously over 15min prior to PET scan when placebo is administered intranasally |
| DRUG | Placebo infusion | 100 ml saline is infused intravenously over 15min prior to PET scan when insulin is administered intranasally |
| RADIATION | [11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO) | Each participant undergoes a 90-min \[11C\]-(+)-PHNO scan twice |
Timeline
- Start date
- 2026-01-01
- Primary completion
- 2029-01-01
- Completion
- 2029-01-01
- First posted
- 2025-11-28
- Last updated
- 2025-11-28
Locations
1 site across 1 country: Austria
Source: ClinicalTrials.gov record NCT07252752. Inclusion in this directory is not an endorsement.